The objective of this poster is to collate relevant literature related to Lu-177 PSMA treatment outcomes and to compare Lu-177 PSMA treatment with other treatment options, i.e. Abiraterone, Enzalutamide, Docetaxel and Cabazitaxel known as a third-line treatment for the metastatic castration-resistant prostate cancer (mCRPC).
Prostate cancer is one of the significant threat to men’s health all over the world and the second leading cause of death in the United States of America.25,000 NZ men are currently living with a diagnosis of prostate cancer (MOH,2018)3000 new cases are being diagnosed with prostate cancer, each year and 560 are likely to die each year from metastatic prostate cancer.
Currently, much attention is being given to the development of precision medicine in oncology. Earlier Radioisotope-labelled choline was used to determine the stage...
Findings and procedure details
Explored database i.e. PubMed, EBSCO, CINAHL, Medline and Google Scholar.Considered peer-reviewed journal articles written in English and published between 2005-2019. The search strategy and selection criteria were based on the peer-reviewed preferred reporting items for systematic reviews and meta-analysis (PRISMA). The search term used for Literature search including “ Lu-177-PSMA”, “mCRPC treatment AND third-line treatment”, “Lu-177-PSMA AND Quality of life”
Reviewed literature found that Lu-177-PSMA based shows comparable results of the existing third-line treatment for mCRPC (see Image 1 and 2).Radionuclide Lu177-PSMA based...
Lu-177-PSMA has shown promising responses in the advanced stage of prostate cancer (mCRPC) and has revealed an indication of becoming an essential treatment option in the future. Low harmfulness of the treatment and easy acceptability with very few episodes of side effects makes it a better choice for the treatment of mCRPC or the advanced stage of prostate cancer. However, there is more trial required to explore treatment options of Lu-177-PSMA and the well-established methods of treatments (second and third-line treatment) in future.
Personal information and conflict of interest
M. Vyas; Auckland/NZ - Author at Unitec Institute of Technology
Ahmadzadehfar, H., Essler, M., Schafers, M., & Rahbar, K. (2016). Radioligand therapy with (177)Lu-PSMA-617 of metastatic prostate cancer has already been arrived in clinical use. Nucl Med Biol, 43(12), 835. https://doi.org/10.1016/j.nucmedbio.2016.08.003
Azad, A. A., Eigl, B. J., Murray, R. N., Kollmannsberger, C., & Chi, K. N. (2015). Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur Urol, 67(1), 23-29. https://doi.org/10.1016/j.eururo.2014.06.045
Baccala, A., Sercia, L., Li, J., Heston, W., & Zhou, M. (2007). Expression of prostate-specific membrane antigen in tumor-associated neovasculature...